TY  - JOUR
TI  - Staphylococcus aureus costochondritis and chest wall abscess
in a COVID-19 patient treated with tocilizumab
AB  - Coronavirus disease 2019 (COVID-19) is a worldwide pandemic, causing a global health threat. Up to 15% of the confirmed cases develop
severe disease, requiring hospitalization or intensive care unit (ICU) admission. Tocilizumab, an IL-6 receptor antagonist, is a promising
treatment of severe pneumonia with acute respiratory distress syndrome (ARDS) or cytokine release syndrome (CRS) in the course of
COVID-19. We report a suppurative costochondritis and chest wall abscess in a severe COVID-19 patient treated with tocilizumab.
AU  - odabasi, zekaver
AU  - Şanal Toprak, Canan
AU  - ergenç, ilkay
DO  - 10.5606/tftrd.2021.8208
PY  - 2021
JO  - Turkish Journal of Physical Medicine and Rehabilitation
VL  - 67
IS  - 3
SN  - 2587-0823
SP  - 382
EP  - 385
DB  - TRDizin
UR  - http://search/yayin/detay/517230
ER  -